21.02.2012 • News

BASF Buys Merck's Electrolytes Business

BASF announced its third acquisition in battery technology in two months, saying it would buy Merck KGaA's electrolytes business for high-performance batteries to tap into growing demand for electric vehicles.

"This acquisition enhances the expertise we offer to automotive and battery manufacturers around the world," BASF board member Andreas Kreimeyer said in a statement on Tuesday.

The two companies did not say how much BASF was paying in the deal, which includes technologies and products Merck developed to boost the performance of batteries, such as additives for electrolytes used to make lithium ion batteries.

Merck said it is selling the business because it has little in common with its other chemicals activities and meets only a fraction of the needs of customers who make batteries.

BASF late last year announced plans to pool all of its battery activities geared towards electromobility into a new business unit, joining the race for next generation lithium-ion battery cells for electric cars.

Since then, it has announced plans to buy U.S.-based nickel-metal hydride battery technology specialist Ovonic Battery as well as a stake in lithium-sulfur battery maker Sion Power.

Stricter laws governing greenhouse gas emissions, depleting fossil fuels and the rising price of crude oil are pushing carmakers across the world to roll out new zero-emission cars that can run entirely on electricity.

Since an electric car costs often twice the price of a conventional car powered by a combustion engine, researchers are searching for a way to make the lithium-ion lighter and less expensive.

 

 

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.